Literature DB >> 21960008

Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease.

Kurt Jellinger1.   

Abstract

Mild cognitive impairment in Parkinson disease (PD-MCI) shows heterogeneity in the clinical presentation, neuropsychology, neuroimaging, and neuropathology, suggesting abnormal metabolic network activities involving several cortical and subcortical systems. Prospective studies using specific biomarkers, including amyloid imaging and CSF biomarkers are important for the diagnosis and prognostic assessment of early cognitive deficits in PD patients.

Entities:  

Mesh：

Year:  2011        PMID： 21960008     DOI： 10.1007/s00702-011-0716-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  22 in total

Review 1.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Neuropathology in Parkinson's disease with mild cognitive impairment.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2010-10-05       Impact factor: 17.088

4.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

Review 5.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

6.  Comparing predictors of conversion and decline in mild cognitive impairment.

Authors:  S M Landau; D Harvey; C M Madison; E M Reiman; N L Foster; P S Aisen; R C Petersen; L M Shaw; J Q Trojanowski; C R Jack; M W Weiner; W J Jagust
Journal:  Neurology       Date:  2010-06-30       Impact factor: 9.910

7.  Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Authors:  D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

Review 8.  [Association of Mild Cognitive Impairment (MCI) and depression].

Authors:  Michaela Defrancesco; Josef Marksteiner; E A Deisenhammer; Hartmann Hinterhuber; Elisabeth M Weiss
Journal:  Neuropsychiatr       Date:  2009

9.  Amyloid imaging in mild cognitive impairment subtypes.

Authors:  David A Wolk; Julie C Price; Judy A Saxton; Beth E Snitz; Jeffrey A James; Oscar L Lopez; Howard J Aizenstein; Ann D Cohen; Lisa A Weissfeld; Chester A Mathis; William E Klunk; Steven T De-Kosky; Steven T DeKoskym
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

Review 10.  Neuropathologic alterations in mild cognitive impairment: a review.

Authors:  William R Markesbery
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472
View more
  7 in total

1.  Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

Authors:  Joseph R Winer; Anne Maass; Peter Pressman; Jordan Stiver; Daniel R Schonhaut; Suzanne L Baker; Joel Kramer; Gil D Rabinovici; William J Jagust
Journal:  JAMA Neurol       Date:  2018-02-01       Impact factor: 18.302

2.  Are Parkinson's Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study.

Authors:  Jacob D Jones; Jared J Tanner; Michael Okun; Catherine C Price; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2017-02-06       Impact factor: 2.892

3.  Brain amyloid and cognition in Lewy body diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Marta Marquie; Andrea L Santarlasci; Dorene M Rentz; Jacqueline Maye; Keith A Johnson; John H Growdon
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

4.  Frontal and posterior subtypes of neuropsychological deficit in Parkinson's disease.

Authors:  Ivy N Miller; Sandy Neargarder; Megan M Risi; Alice Cronin-Golomb
Journal:  Behav Neurosci       Date:  2013-02-11       Impact factor: 1.912

5.  A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies.

Authors:  Giovanni Bellomo; Federico Paolini Paoletti; Elena Chipi; Maya Petricciuolo; Simone Simoni; Nicola Tambasco; Lucilla Parnetti
Journal:  Diagnostics (Basel)       Date:  2020-11-26

6.  Remission of cognitive deficits in Parkinson's disease: recovery from a nonamnestic mild cognitive impairment or psychiatric symptoms remission?

Authors:  Jonas Jardim de Paula; Marco Túlio Gualberto Cintra; Débora Marques Miranda; Maria Aparecida Camargos Bicalho; Edgar Nunes Moares; Leandro Fernandes Malloy-Diniz
Journal:  Case Rep Psychiatry       Date:  2012-11-05

7.  Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study.

Authors:  Shu-Yang Yu; Li-Jun Zuo; Fang Wang; Ze-Jie Chen; Yang Hu; Ya-Jie Wang; Xiao-Min Wang; Wei Zhang
Journal:  BMC Neurol       Date:  2014-05-22       Impact factor: 2.474
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.